Formic Acid

Formic Acid

SCHEMBL5209726

CN1CCC(C(=O)c2cccc(NC(=O)Nc3ccc(F)c(F)c3F)c2)CC1.O=CO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1F P30939 10/20 0.58
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CCR3 P51677 1/20 0.42
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EPHX2 P34913 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
KDR P35968 1/20 0.41
CHRM5 P08912 1/20 0.40
DRD5 P21918 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1E P28566 1/20 0.40
HTR7 P34969 1/20 0.40
OPRK1 P41145 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL27471303 0.91 HTR1F (0.56) HTR1FKMT2AMEN1NPC1POLB
SCHEMBL5216049 0.89 HTR1F (0.64) HTR1FKMT2AMEN1CCR3EPHX2
SCHEMBL5209945 0.85 HTR1F (0.60) HTR1FKMT2AMEN1NPC1POLB
SCHEMBL5213054 0.84 HTR1F (0.65) HTR1FKMT2AMEN1CCR3EPHX2
SCHEMBL5210434 0.84 HTR1F (0.65) HTR1FKMT2AMEN1CCR3NPC1
SCHEMBL5212023 0.84 HTR1F (0.67) HTR1FKMT2AMEN1NPC1RAB9A
SCHEMBL5211871 0.83 HTR1F (0.64) HTR1FKMT2AMEN1CCR3EPHX2
SCHEMBL5211786 0.81 HTR1F (0.73) HTR1FKMT2AMEN1NPC1RAB9A
SCHEMBL5215502 0.81 HTR1F (0.70) HTR1FKMT2AMEN1CHRM5DRD5
SCHEMBL5215404 0.80 HTR1F (0.72) HTR1FKMT2AMEN1EPHX2CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1153013-B1 5-HT1F AGONISTS LILLY CO ELI (US) 2007-10-31 EP disclosed
EP-1841427-A2 COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID Pozen, Inc. (US) 2007-10-10 EP disclosed
US-20060178349-A1 Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID POZEN INC. (US) 2006-08-10 US disclosed
WO-2006081127-A2 COMPOSITIONS AND THERAPEUTIC METHODS UTILIZING A COMBINATION OF A 5-HT1F INHIBITOR AND AN NSAID POZEN INC. (US) 2006-08-03 WO disclosed
US-6777428-B1 INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS ELI LILLY AND COMPANY 2004-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178349-A1 Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID HTR1F, HTR1A, HTR1E HTR1F 1/4885KMT2A 3859/4885MEN1 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.